Colin Stott,Marnie Duncan,Vincenzo Di Marzo,Cristoforo Silvestri,Andrea Martella
申请号：
US15321778
公开号：
US10039724B2
申请日:
2015.06.29
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The liver plays a key role in regulating total body energy homeostasis and its ability to do so is greatly affected by the occurrence of pathological conditions such as hepatosteatosis or non-alcoholic fatty liver disease (NAFLD), which contributes to hepatic insulin resistance and potentially end-stage liver disease-related mortality. Triglyceride accumulation in hepatocytes of steatotic livers results from the incorporation of plasma free fatty acids as well as de novo fat synthesis. The present invention relates to the use of 7-hydroxy-cannabidiol (7-OH-CBD) in the treatment of non-alcoholic fatty liver disease (NAFLD). Treatment of NAFLD involves lowering the triglyceride levels in a patient's blood stream.
